Literature DB >> 8380452

Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS.

C L Talarico1, W C Phelps, K K Biron.   

Abstract

Patients with AIDS often experience recurrent infections with varicella-zoster virus (VZV) requiring repeated or prolonged treatment with acyclovir (ACV), which may lead to the development of ACV resistance. The ACV resistance of isolates recovered from such patients is associated with diminished VZV thymidine kinase (TK) function. We determined the nucleotide sequences of the TK genes of 12 ACV-resistant VZV strains purified from nine patients with AIDS. Five VZV strains contained nucleotide deletions in their TK genes, introducing a premature termination codon which is expected to result in the production of a truncated protein. No detectable full-length TK protein could be immunoprecipitated from extracts of cells infected with these virus strains. These TK-deficient strains were cross resistant to the TK-dependent antiviral agents ACV, 9-(4-hydroxy-3-hydroxymethylbutyl-yl)guanine (penciclovir), and 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (BVaraU). The remaining seven strains each contained a nucleotide change that resulted in an amino acid substitution in the TK protein. These substitutions occurred throughout the TK protein, namely, in the ATP-binding site, the nucleoside-binding site, between the two binding sites, and at the carboxy terminus of the protein. We determined the effects of these mutations on the stability of TK protein expression in virus-infected cells and on the sensitivity of mutants to the TK-dependent antiviral agents ACV, BVaraU, and penciclovir.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380452      PMCID: PMC237457     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.

Authors:  S Safrin; T G Berger; I Gilson; P R Wolfe; C B Wofsy; J Mills; K K Biron
Journal:  Ann Intern Med       Date:  1991-07-01       Impact factor: 25.391

2.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

3.  The role of herpes simplex virus type 1 thymidine kinase in pathogenesis.

Authors:  S Efstathiou; S Kemp; G Darby; A C Minson
Journal:  J Gen Virol       Date:  1989-04       Impact factor: 3.891

4.  In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.

Authors:  E L Hill; G A Hunter; M N Ellis
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate.

Authors:  P A Furman; M H St Clair; J A Fyfe; J L Rideout; P M Keller; G B Elion
Journal:  J Virol       Date:  1979-10       Impact factor: 5.103

6.  Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU.

Authors:  H Machida; Y Watanabe
Journal:  Microbiol Immunol       Date:  1991       Impact factor: 1.955

7.  Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.

Authors:  G B Roberts; J A Fyfe; R K Gaillard; S A Short
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

8.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

9.  Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1.

Authors:  D M Coen; P A Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

10.  Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial.

Authors:  J C Wade; B Newton; C McLaren; N Flournoy; R E Keeney; J D Meyers
Journal:  Ann Intern Med       Date:  1982-03       Impact factor: 25.391

View more
  22 in total

1.  Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.

Authors:  T I Ng; Y Shi; H J Huffaker; W Kati; Y Liu; C M Chen; Z Lin; C Maring; W E Kohlbrenner; A Molla
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Mutation hot spots in the canine herpesvirus thymidine kinase gene.

Authors:  Shinya Yamada; Yasunobu Matsumoto; Yasuhiro Takashima; Haruki Otsuka
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

3.  Drug-resistant herpesviruses: should we look for them?

Authors:  G Boivin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

4.  Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir.

Authors:  F Morfin; D Thouvenot; M De Turenne-Tessier; B Lina; M Aymard; T Ooka
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

Authors:  R T Sarisky; M R Quail; P E Clark; T T Nguyen; W S Halsey; R J Wittrock; J O'Leary Bartus; M M Van Horn; G M Sathe; S Van Horn; M D Kelly; T H Bacon; J J Leary
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Identification and analysis of the simian varicella virus thymidine kinase gene.

Authors:  C Y Pumphrey; W L Gray
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.

Authors:  Hikaru Fujii; Shizuko Harada; Tomoki Yoshikawa; Souichi Yamada; Natsumi Omura; Miho Shibamura; Takuya Inagaki; Hirofumi Kato; Shuetsu Fukushi; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

8.  In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus.

Authors:  S Safrin; L Phan
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 9.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

10.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.